Curcumin Derivative MRI Agent for Amyloid Beta Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Alzheimer's disease, such as PET and MRI, face challenges including low sensitivity, radiation concerns, and difficulty in detecting amyloid β peptide aggregates, which are believed to cause neuronal cell death, due to limitations in crossing the blood-brain barrier and specificity.
Innovation Solution
A curcumin derivative or its salt with a specific chemical structure exhibiting keto-enol tautomerism, allowing it to bind and release from amyloid β peptide aggregates, is developed for use as a diagnostic imaging agent, providing high affinity and sensitivity for MRI and potentially reducing adverse reactions by radioactive labeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If radioactive contrast media are used for PET and SPECT imaging, then detection sensitivity and specificity for amyloid β proteins are improved, but radiation exposure and adverse reactions increase
Solution Approach 1:
The patent employs a non-radioactive curcumin derivative contrast agent that can be administered repeatedly without the cumulative radiation damage concerns of radionuclides. The compound is designed to be excreted quickly from the body, allowing for repeated imaging studies without long-term radiation exposure risks.
Solution Approach 2:
The invention replaces the nuclear physics-based detection method (radioactive decay detection in PET/SPECT) with a magnetic resonance-based method. This substitution eliminates ionizing radiation while maintaining imaging capability through the magnetic properties of the curcumin derivative when bound to amyloid β proteins.
2Object-affected harmful factors
If conventional MRI contrast media are used, then radiation exposure is reduced, but detection sensitivity and specificity for amyloid β peptide aggregates remain low
Solution Approach 1:
The curcumin derivative is designed with specific molecular characteristics that enable selective binding to amyloid β peptide aggregates. The compound's structure includes functional groups that specifically interact with the β-sheet structures of amyloid aggregates, providing local concentration enhancement at the target site while maintaining low background signal.
Solution Approach 2:
The patent uses a curcumin derivative with specific chemical modifications including fluorine atoms and hydroxyl groups at defined positions. This composite molecular structure combines the amyloid-binding capability of curcumin with MRI-active fluorine nuclei, creating a dual-function contrast agent that provides both specificity and detectability.
3Measurement precision
If contrast media with high amyloid affinity are used, then binding specificity is improved, but excretion rate decreases leading to prolonged retention in the body
Solution Approach 1:
The curcumin derivative exhibits dynamic binding behavior with amyloid β aggregates, characterized by rapid association and dissociation rates. This dynamic equilibrium allows the compound to bind specifically to targets for imaging while also being readily released and excreted, preventing prolonged retention. The molecular design includes flexible linkers and soluble groups that facilitate rapid turnover.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound enables early diagnosis of Alzheimer's disease by specifically binding to amyloid β proteins, offering higher sensitivity and quicker excretion, thus reducing radiation exposure and improving detection efficiency compared to conventional methods.
Implementation Method 1
selectively bind to intracerebral amyloid β proteins
Implementation Method 2
A diagnostic imaging agent and an in-vitro diagnostic agent for a disease in which amyloid β peptide aggregates accumulate, which utilize a keto-enol tautomerism
Implementation Method 3
nuclear magnetic resonance imaging method (MRI)
Data Source
AI summary
Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I):(wherein R1a and R1b are each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; R2s are each independently a fluorine atom, CHF2—, CF3—, CHF2O—, or CF3O—; R3s are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R4—(CH2)m—; R4 is hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONR5R6; R5 and R6 are each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid β peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid β peptide aggregate.